Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4318-4328

  Ueda, Shigeto ^a,c   Roblyer, Darren ^a   Cerussi, Albert ^a   Durkin, Amanda ^a   Leproux, Anais ^a   Santoro, Ylenia ^a   Xu, Shanshan ^a   O'Sullivan, Thomas D ^a   Hsiang, David ^b   Mehta, Rita ^b   Butler, John ^b   Tromberg, Bruce J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEOXYHEMOGLOBIN; DOXORUBICIN; ESTROGEN RECEPTOR; HEMOGLOBIN; OXYHEMOGLOBIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD FLOW VELOCITY; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DIFFUSE OPTICAL SPECTROSCOPIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISCRIMINANT ANALYSIS; ECHOMAMMOGRAPHY; FEMALE; GLUCOSE TRANSPORT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MOLECULAR IMAGING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPECTROMETRY; TISSUE METABOLISM; TISSUE OXYGENATION; TISSUE PERFUSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; TREATMENT OUTCOME;

EID: 84865742015     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0056     Document Type: Article

References (48)

1. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
2. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
4. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006;11:574-89.
5. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
6. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
7. Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008;26:2636-43.
8. Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Duenas-Garcia R, Jaen-Morago A, Ortega-Granados AL, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 2008;10:646-53.
9. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
10. Bevilacqua F, Berger AJ, Cerussi AE, Jakubowski D, Tromberg BJ. Broadband absorption spectroscopy in turbid media by combined frequency-domain and steady-state methods. Appl Opt 2000;39:6498-507.
11. Pakalniskis MG, Wells WA, Schwab MC, Froehlich HM, Jiang S, Li Z, et al. Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology 2011;259:365-74.
12. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008;8:705-13.
13. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316-22.
14. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 1993;26:631-6.
15. Finlay JC, Foster TH. Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady-state diffuse reflectance at a single, short source-detector separation. Med Phys 2004;31:1949-59.
16. Finlay JC, Foster TH. Recovery of hemoglobin oxygen saturation and intrinsic fluorescence with a forward-adjoint model. Appl Opt 2005;44:1917-33.
17. Wang HW, Zhu TC, Putt ME, Solonenko M, Metz J, Dimofte A, et al. Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt 2005;10:14004.
18. Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ. In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J Biomed Opt 2006;11:044005.
19. Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad SciUSA2007;104:4014-9.
20. Soliman H, Gunasekara A, Rycroft M, Zubovits J, Dent R, Spayne J, et al. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res 2010;16:2605-14.
21. Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 2008;10:1028-40.
22. Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, et al. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 2009;252:551-60.
23. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-59.
24. Uematsu T, Kasami M, Yuen S. Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol 2010;20:2315-22.
25. Li XR, Cheng LQ, Liu M, Zhang YJ, Wang JD, Zhang AL, et al. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 2012;29:425-31.
26. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010;49:354-60.
27. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14.
28. Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010;16:2803-10.
29. Cerussi A, Siavoshi S, Durkin A, Chen C, Tanamai W, Hsiang D, et al. Effect of contact force on breast tissue optical property measurements using a broadband diffuse optical spectroscopy handheld probe. Appl Opt 2009;48:4270-7.
30. Acrin 6691 Training Videos. 2012. [cited Jan 6, 2012]. Available from: http://acrin.bli.uci.edu/trainingvideos.
31. Roblyer D, Ueda S, Cerussi A, Tanamai W, Durkin A, Mehta R, et al. Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A 2011;108:14626-31.
32. Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, et al. Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005;7:279-85.
33. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
34. Vergara IA, Norambuena T, Ferrada E, Slater AW, Melo F. StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 2008;9:265.
35. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520-5.
36. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010;119:315-23.
37. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 2009;18 Suppl 3:S137-40.
38. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
39. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010;17:2411-8.
40. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
41. Racker E. Warburg effect revisited. Science 1981;213:1313.
42. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
43. Vaupel P, Thews O, Kelleher DK, Hoeckel M. Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 1998;174 Suppl 4:6-12.
44. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-54.
45. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007;85:139-48.
46. Fujimoto JG, Farkas DL, editors. Biomedical optical imaging. New York, NY: Oxford University Press; 2009.
47. Boas DA, Pitris C, Ramanujam N, editors. Handbook of biomedical optics. Boca Raton, FL: CRC Press; 2011.
48. Hohenberger P, Felgner C, Haensch W, Schlag PM. Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 1998;48:97-106.